Capstone Therapeutics (NASDAQ:CAPS) Posts Earnings Results

Capstone Therapeutics (NASDAQ:CAPS) issued its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.21), FiscalAI reports. The company had revenue of $21.48 million during the quarter, compared to analyst estimates of $20.39 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.

Capstone Therapeutics Price Performance

Shares of NASDAQ CAPS traded down $0.09 during midday trading on Wednesday, reaching $0.22. The company’s stock had a trading volume of 9,018,864 shares, compared to its average volume of 1,896,040. The company has a current ratio of 0.95, a quick ratio of 0.29 and a debt-to-equity ratio of 0.79. The company has a 50 day moving average price of $0.27 and a 200 day moving average price of $0.44. Capstone Therapeutics has a one year low of $0.21 and a one year high of $2.07. The company has a market cap of $3.41 million, a price-to-earnings ratio of -0.07 and a beta of -1.52.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent filing with the Securities & Exchange Commission. 2.55% of the stock is owned by institutional investors and hedge funds.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.